Back Home Search

HR+/HER2 neg

    • Protocols
    • UW21002

      OPEN TO ACCRUAL

      PII Trial of ctDNA-Guided 2nd line Adjuvant Therapy for High Risk, Stage II-III, ER+ HER2- BC (DARE)

    • UW22102

      OPEN TO ACCRUAL

      RaPhLRR: PII Ribociclib + Endocrine Tx for Recurrent, Resected HR+ HER2- Breast Cancer

    • NRGBR009

      OPEN TO ACCRUAL

      Trial Evaluating Addition of Adjuvant Chemo to Ovarian Function Suppression + Endocrine Therapy

    • UW23102

      OPEN TO ACCRUAL

      Cambria-2: Adjuvant Endocrine-based Therapy of Camizestrant in ER+/HR2- Early BC